


PRODUCT INFORMATION



Lorglumide (sodium salt)

Item No. 17555

CAS Registry No.: 1021868-76-7
Formal Name: 4-[(3,4-dichlorobenzoyl)amino]-5-(dipentylamino)-5-oxo-pentanoic acid, monosodium salt
MF: C₂₂H₃₁Cl₂N₂O₄ • Na
FW: 481.4
Purity: ≥98%
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Lorglumide (sodium salt) is supplied as a crystalline solid. A stock solution may be made by dissolving the lorglumide (sodium salt) in the solvent of choice, which should be purged with an inert gas. Lorglumide (sodium salt) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of lorglumide (sodium salt) in these solvents is approximately 1 mg/ml.

Lorglumide (sodium salt) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, lorglumide (sodium salt) should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Lorglumide (sodium salt) has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Cholecystokinin (CCK) is a peptide hormone that, through specific receptors, induces pancreatic growth and enzyme secretion, smooth muscle contraction in the gall bladder and stomach, and modulates feeding and behavior.¹⁻³ Lorglumide is a nonpeptidic antagonist of the CCK A receptor (CCK₁; IC₅₀ = 50 nM) that is 60-fold less effective at the CCK B receptor (CCK₂; IC₅₀ = 3 μM).⁴ It blocks CCK-mediated gut muscle contraction, pancreatic growth, and pancreatic secretion.⁵⁻⁷ Lorglumide is commonly used to study the roles of CCK₁ in tissues and in animals.^{8,9}

References

1. Sabbatini, M.E., Chen, X., Ernst, S.A., et al. *J. Biol. Chem.* (2008).
2. Murphy, K.G. and Bloom, S.R. *Exp. Physiol.* **89**(5), 507-516 (2004).
3. Wynne, K., Stanley, S., and Bloom, S. *J. Clin. Endocrinol. Metab.* **89**(6), 2576-2582 (2004).
4. Makovec, F., Peris, W., Revel, L., et al. *J. Med. Chem.* **35**(1), 28-38 (1992).
5. Barthó, L., Holzer, P., Lembeck, F., et al. *Br. J. Pharmacol.* **90**, 753-761 (1987).
6. Niederau, C., Liddle, R.A., Williams, J.A., et al. *Gut* **28**, 63-69 (1987).
7. Scarpignato, C., Varga, G., Dobronyi, I., et al. *Br. J. Pharmacol.* **96**, 661-669 (1989).
8. Gamble, J., Kenny, S., and Dockray, G.J. *Regul. Pept.* **185**, 9-13 (2013).
9. Lo, C.C., Davidson, W.S., Hibbard, S.K., et al. *Endocrinology* **155**(5), 1700-1707 (2014).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/24/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM